Kornimate/medical-research-clean huggingface dataset:
digital follow-up program for people with chronic obstructive pulmonary disease in primary healthcare

Conditions: COPD Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd), characterized by non-reversible airflow obstruction, contributes to high mortality and morbidity rates worldwide, including norway. individuals with copd experience symptoms and complications that impede daily activities and diminish their quality of life. copd places a growing burden on healthcare systems presently and in the future. interventions to empower individuals to self-manage their health effectively are needed to help the challenges of living with copd, and work towards a sustainable healthcare system. as part of the broader healthcare policy agenda, this project aligns with the increasing emphasis on digital homebased primary healthcare. the intervention in this study will combine digital homebased care and guided self-determination follow-ups (gsd) within a general practice setting. this project consists of 1) explore the feasibility of a copd specific gsd counselling program delivered within a digital platform in primary care, 2) explore patients' and nurses' experiences applying the program, 3) examine the treatment fidelity of the intervention amongst healthcare professionals. this project is a pilot cluster-randomized controlled trial (rct), including individuals diagnosed with copd, conducted in primary healthcare settings, and assessment of feasibility and uncertainties before conducting a later full-scale cluster-rct. the intervention draws upon the medical research council's revised guidelines for developing complex intervention studies, focusing on the initial phases of intervention development and pilot testing. primary care clinics are randomly assigned into either an intervention- or a control group. the intervention consists of the gsd counselling program with follow-up within a digital platform. the control group provide regular care. the project will include both qualitative (individual semi-structured interviews), and quantitative data (questionnaires and clinical data). in conclusion, this project explores an innovative intervention offering personalized strategies for copd management in primary care clinic, by containing a digitalized homebased care program and follow-ups. the study aims to improve the daily living for people with copd, while contributing to the future sustainability of healthcare systems.


Eligibility criteria:
inclusion criteria: * diagnosed with copd living at home * post-bronchodilator forced expiratory volume 1 s (fev1) to forced vital capacity (fvc) below lower limit of normality exclusion criteria: * severe somatic disease * severe psychiatric diagnosis * not able to provide informed consent * do not write, speak or understand norwegian

Keywords: copd guided self-determination primary healthcare randomized controlled trial web-based follow-up
use of procalcitonin, a blood test to guide antibiotic therapy for sepsis in adults

Conditions: Sepsis

Summary: trial design: randomised controlled, two-arm, parallel, clinical trial to assess the efficacy and safety of sequential daily procalcitonin assessments to guide de-escalation of empirical antibiotic therapy in adult patients with sepsis. trial settings trial site is chattogram medical college hospital (cmch), bangladesh. cmch is tertiary care hospital with undergraduate and postgraduate teaching facilities. this tertiary hospital receives referrals from urban and rural areas of southern bangladesh and has basic facilities for intensive care and haemodialysis. trial participants: male or female hospitalised patients, 16-65 years of age, with confirmed or suspected sepsis patients (total 532) will be 1:1 randomised to either: * intervention arm: daily measurement of serum procalcitonin concentrations to guide de-escalation of antibiotics (intervention arm: 266), or * control arm: standard of practice to guide de-escalation of antibiotics without procalcitonin assessments (control arm: 266). patients will be followed-up until icu discharge and/or hospital discharge with an additional follow-up at 28 days after discharge. funder: wellcome trust of great britain grant reference number from wellcome trust: 220211/a/20/z


Eligibility criteria:
inclusion criteria: * participant, legally authorised person/ legal guardian willing and able to give informed consent for participation in the trial. * male or female, aged 16 to 65 years * suspected or proven bacterial infection * a positive sepsis screening national early warning score (news) equal or greater than 5 (table 1 or at least one criterion with a score of 3. * intention to start parenteral antibiotic therapy * within 24 hours of hospital admission exclusion criteria: * patients with suspected/documented tuberculosis, parasitic infection (including malaria or visceral leishmaniasis), or viral infections (i.e., covid-19, dengue, hiv) * pregnancy * intended for a short stay in icu or general ward (such as post-operative) * patients requiring a predefined long course of antibiotic therapy (such as endocarditis, osteomyelitis, lung abscess, liver abscess, septic arthritis) * immunocompromised patients, including as severe neutropenia (\< 500 cells/ml), transplant recipients, on prolonged corticosteroid treatment, chemotherapy or disease modifying immunomodulatory medications * more than 48 hours of parenteral antibiotic use * surgical patients, including patients with a surgical septic source or patients requiring source control, i.e. abscess drainage * moribund patients or patients receiving end of life care * previous enrolment in procalban * conditions accompanied with a systemic inflammatory state, including pancreatitis, cardiogenic shock, severe trauma
pregnancy outcome in woman with threatened abortion

Conditions: Threatened Abortion

Summary: the study aims to quantify the relations between first \& second trimester bleeding and maternal \& neonatal morbidity. additionally, the study will help in assessing the risk for abortions in women with threatened abortions and the risk factors for threatened abortion.

the study is following woman retrospectively through their pregnancy from the first trimester troughout delivery . we will measure the relation between first and/or second trimester bleeding ( threatend abortion ) and pregnancy outcome ( as written below ) - maternal and neonatal .

Eligibility criteria:
inclusion criteria: * women who attended the emergency department with vaginal bleeding and/or abdominal pain and were on their 20th week of pregnancy or less. exclusion criteria: * women with any background that can explain vaginal bleeding or any other circumstance that can explain it.
evaluation of the success rate of prefabricated versus conventional band and loop space maintainers in children with prematurely lost first primary molars

Conditions: Premature Tooth Exfoliation

Summary: to assess the clinical efficacy of prefabricated space maintainers compared to conventional ones, focusing on preserving the integrity of each component of bands and loops, avoidance of soft tissue impingement as well as preservation of arch dimensions.

management of the developing occlusion lies firmly within the scope of pediatric dentistry, therefore protection of dental arch integrity and inter-arch relations in the premature loss of teeth can be guaranteed by placing space maintainers. conventional appliances are used successfully as space maintainers, although they have some disadvantages.the need for at least two visits to delivery, therefore cannot be planned in patients under general anesthesia. fabrication of conventional and loop requires an alginate impression and laboratory work. prefabricated band and loop devices have been introduced to dentistry in recent times. they can possibly overcome most of the previously mentioned limitations of conventional space maintainers. the prefabricated band and loop space maintainer is adjusted and applied in one visit and therefore can be planned in patients under general anesthesia. other advantages include less time, more patient and parent satisfaction, and no laboratory work

Eligibility criteria:
inclusion criteria: * clinical criteria medically free children. * patient and parent showing cooperation and compliance. * patients having mandibular first deciduous molar indicated for extraction due to extensive coronal caries beyond possible repair, root caries and/or failed pulp therapy. * freshly extracted single molars unilaterally or bilaterally * unilateral or bilateral loss of primary molars before or after the eruption of the first permanent molar * caries free or restored the mandibular second primary molars and deciduous canines in the side of the extraction maintained throughout the entire follow-up period. radiographic criteria * presence of succedaneous tooth bud. * presence of at least 1 mm bone overlying the succedaneous tooth germ * 1/3 to less than 2/3 of the root of the permanent successor is formed to the prematurely lost primary molars. exclusion criteria: * • children with any parafunctional habits. * children with previous allergies to stainless steel. * permanent successors with 2/3 of its roots formed and space analysis does not indicate the fabrication of space maintainer.
lenvatinib combined anti-pd1 antibody for the advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Anti-PD1 Antibody; Liver Diseases

Summary: for the advanced hepatocellular carcinoma (hcc), the targeted therapy and immunotherapy are recommended. this study focused on the management of lenvatinib combined anti-pd1 antibody for the hcc. this study will create a database that will provide clinical parameters and outcomes of patients undergoing lenvatinib and anti-pd1 antibody as part of their standard of care in hopes of answering key clinical questions.

lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. the programmed cell death protein-1 (pd-1) antibody, was effective and tolerable in patients with hepatocellular carcinoma and portal vein tumor thrombus. we aimed to describe the efficacy and safety of lenvatinib combined anti-pd1 antibody in patients with hepatocellular carcinoma who can not receive redical therapy.

Eligibility criteria:
inclusion criteria: 1. hcc diagnosed by histopathological examination or guidelines for diagnosis and treatment of primary liver cancer or the recurrent hcc after surgery; 2. age between 18 and 75 years; 3. stage b (middle stage) or c (late stage) hcc determined in accordance with barcelona clinic liver cancer staging system (bclc stage). in case of stage b. 4. previous use of any systemic therapy but intolerant, impotent or drug resistant. 5. child-pugh class a or b; 6. eastern cooperative group performance status (ecog) score of 0-2; 7. hemoglobin ≥ 8.5 g/dl total bilirubin ≤ 30mmol/l serum albumin ≥ 32 g/l asl and ast ≤ 5 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal inr ≤ 1.5 or pt/aptt within normal limits absolute neutrophil count (anc) \>1,500/mm3 8. prothrombin time ≤18s or international normalized ratio \< 1.7. 9. ability to understand the protocol and to agree to and sign a written informed consent document. exclusion criteria: 1. cholangiocellular carcinoma (icc); 2. patients with cancer thrombus in the main trunk of portal vein (vp4), or cancer thrombus in inferior vena cava should be excluded; 3. the survival or patients less than 3 months. 4. serious medical comorbidities. 5. evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy 6. known history of hiv 7. history of organ allograft 8. known or suspected allergy to the investigational agents or any agent given in association with this trial. 9. cardiac ventricular arrhythmias requiring anti-arrhythmic therapy 10. evidence of bleeding diathesis. 11. patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.

Keywords: tislelizumab lenvatinib toripalimab sintilimab camrelizumab keytruda opdivo
a new oral salivary equivalent compared to two moisturizing mouth sprays in patients with xerostomia: niagara study

Conditions: Xerostomia; Hyposalivation; Head and Neck Cancer; Sjögren Syndrome

Summary: the purpose of this study is to evaluate the clinical efficacy, safety and acceptability of our new oral salivary equivalent in the relief of signs and symptoms related to mouth dryness as compared to two distinct moisturizing currently marketed oral sprays (aequasyal® \& biotene®) in patients with xerostomia due to chronic hyposalivation.

national, multicentre, randomised, active controlled, crossover, open-label study using a 3-latin-square design. 200 evaluable patients have been recruited

Eligibility criteria:
inclusion criteria: patients: * aged 18 years or more, * clinical diagnosis of xerostomia by a severe reduction of salivation, as detected by patient's answers to few specific questions and measured by saliva volume at screening visit (test of saliva weight absorbed ≤ 0.1g/min) * any medical condition or treatment leading to a severe reduction of salivation related to either: * head and neck radiation therapy for cancer, * gougerot-sjögren syndrome * medications known to induce xerostomia (psychotropic drugs, antihypertensive drugs) * dehydration, hypothyroidism, parkinson's disease and/or diabetes mellitus * female patients must be post-menopausal or using a highly effective method for avoidance of pregnancy throughout the whole study duration, if childbearing potential. * able to understand and comply with the protocol procedures * willing and able to give their written informed consent * affiliated to the french national health insurance program exclusion criteria: * known hypersensitivity to one of the study products or to one of their components * any planned change in dosing of all known medications inducing mouth dryness * concomitant treatment for xerostomia symptoms without a scheduled 3 to 7-day withdrawal window * oral candidiasis as diagnosed by a microbiological test obtained from an unstimulated whole saliva sample until 3-week period from disease release * oral ulceration * alcohol (\>2 glasses of wine/day), smoking (\>10 cigarettes/day), caffeine and/or theine intake (\>4 cups/day) * patients unable to fill out the questionnaires or to comply with the study protocol * dental infection * patients participating to another clinical trial at the time of the study entry or within 30 days prior to study enrolment * life-threatening condition at the time of the study * pregnant or lactating women and women of childbearing potential refusing to use adequate contraception.

Keywords: cross-over salivary equivalent dry mouth medical device
together in recovery with veterans through employment

Conditions: Veterans With Opioid Use Disorder

Summary: the purpose of this study is to help veterans who have opioid use problems with gaining and maintaining meaningful employment. the investigators also want to know employment helps with other aspects of the veteran's life including starting and staying on necessary medications, mental health needs, and feeling a part of society.

the primary aim of this study is to evaluate the employment outcomes of individual placement and support (ips) compared to treatment-as-usual vocational rehabilitation (tau-vr) in 120 veterans who are recovering from opioid use disorder (oud) over 15 months. specifically, the investigators will see which treatment yields more weeks worked in a competitive job with the hypothesis that ips will result in better outcomes than tau-vr. the investigators will interview veterans in both ips and tau-vr groups to investigate the contextual barriers and facilitators of implementing vocational services among veterans with oud with the aim to provide solutions and leverage facilitators of success as the vha expands supported employment services to a new priority population. investigators will evaluate the impact of vocational services on adherence to prescribed treatment and oud relapse rates. this study is especially timely given the societal impact of the covid-19 pandemic on employment and occupational functioning.

Eligibility criteria:
inclusion criteria: * age 19\* (\<19 year of age in the state of al is defined minor) * dsm-5 axis i diagnosis of oud * currently unemployed or underemployed, defined as working \<20hrs/week in a meaningful competitive job for a wage, salary, or commission * expression of interest in competitive employment; and willing and able to give informed consent exclusion criteria: * current diagnosis of psychotic disorders since these veterans already can receive ips in usual care at tvamc and bvamc * diagnosis of dementia (evidenced in the medical record) * presence of current severe and unstable medical condition or terminal illness, that would contraindicate study participation or expose them to an undue risk * unlikely that participant can complete the study * e.g., expected deployment, incarceration, long-term hospitalization, or relocation from the vicinity * active suicidal or homicidal ideation making it unsafe for veteran to be included * current participation in another vocational interventional trial

Keywords: veteran opioid use disorder employment social support mental health
a trail of cdk4 / 6 inhibitor and mek inhibitor in the treatment of metastatic digestive system tumors

Conditions: Digestive System Tumors

Summary: this is a prospective, open, phase i clinical study to evaluate the safety and tolerability of a cdk4 / 6 inhibitor and a mek inhibitor in the treatment of metastatic digestive system tumors


Eligibility criteria:
inclusion criteria: 1. aged 18-75 years; 2. ecog score ≤ 1; 3. patients with advanced kras mutation or metastatic digestive system tumor confirmed by histology or cytology and imaging diagnosis; 4. according to recist1.1, there was at least one measurable lesion; 5. the expected survival time was more than 12 weeks; exclusion criteria: 1. patients who received any anti-tumor treatment within 4 weeks before enrollment, including radiotherapy, chemotherapy, molecular targeted therapy and immunotherapy, or participated in another intervention clinical trial; 2. previous treatment with targeted braf, mek, erk or cdk family related inhibitors; 3. the third space effusion (such as massive pleural effusion or ascites) with clinical symptoms that cannot be controlled by drainage or other methods; 4. allergy to any test drug and its excipients, or serious allergic history, or contraindication of the test drug; 5. have a history of immunodeficiency, including hiv positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
mechanisms underlying impaired diabetic wound healing

Conditions: Non-healing Wounds; Diabetes

Summary: the overall aim of this research is to utilize wound derived inflammatory cells from diabetic versus non diabetic human chronic wounds to understand mechanisms that are responsible for disregulated inflammation in individuals with diabetes. biology of normal (peripheral blood derived cells) versus wound derived cells will also be studied.

specific aims: 1. to study biology of wound derived inflammatory cells and fluid from diabetic versus non diabetic wounds. 2. to characterize mechanisms that are responsible for dysregulated wound inflammatory cell function in individuals with diabetes. 3. to characterize differences in the biology of normal peripheral blood derived cells versus wound derived cells. the long-term goal of this study is to determine the molecular mechanisms underlying impaired wound healing in diabetics.

Eligibility criteria:
inclusion criteria: * ages 21-80 * chronic wound (present \>4 weeks) * diabetic \& non-diabetic * adult surgical wounds exclusion criteria: * inability to consent * pregnant women * therapeutically immunocompromised * individuals defined in 45 cfr 46 subparts b,c, and d, nor from any other population considered vulnerable 2.9

Keywords: wound healing diabetes inflammatory cell monocyte leukocyte macrophage
retrospective review on uterovaginal anomalies

Conditions: Abnormalities Uterine; Vaginal Abnormality

Summary: review of surgical outcomes of patient who have undergone surgery for uterovaginal anomalies. case notes of patients would be reviewed and data would be gathered for statistical analysis.

uterovaginal anomalies are congenital malformations of the female reproductive tract, including hymenal, vaginal, cervical and uterine anomalies. the incidence could be as high as 7% in females1. these anomalies can occur alone or in association with other anomalies such as renal anomalies. there could be variable consequences from these malformations, some are asymptomatic while some may have various symptoms. it is important to be aware that obstructive uterovaginal anomalies, examples including imperforated hymen and obstructive hemivagina and ipsilateral renal anomaly (also known as ohvira), may present after puberty, with symptoms including amenorrhoea, dysmenorrhea, pelvic pain etc. these are conditions that should be managed. patient may require interventions. surgery is the principal management for obstructive anomalies, dependent on the types of obstruction. types of surgeries ranges from simple surgical procedures to complex surgeries that require multidisciplinary input. post-operatively patients should be offered follow up for monitoring in view of the risk of stenosis that may require ongoing dilation or additional surgical management. there are limited studies on the post-operative outcomes for uterovaginal anomalies, so this study aims at reviewing and comparing the different outcomes after initial surgery. this is a retrospective observational study. electronic and paper clinical records of all patients who attended the prince of wales hospital, alice ho miu ling nethersole hospital and north district hospital with the diagnosis of uterovaginal anomaly will be reviewed, data collected will be input and analyzed using different statistical analysis tools. data between 1.1.2000 and 31.12.2023 will be reviewed retrospectively. no human subject will be recruited. the aim of the study is to reviewing and comparing the different outcomes after surgery for patients who had uterovaginal anomalies

Eligibility criteria:
inclusion criteria: * all patients who attended the prince of wales hospital with the diagnosis of uterovaginal anomaly since 2000 exclusion criteria: * nil